Funding

Health

Pharmac funds injectable letermovir to protect transplant patients from CMV

Pharmac estimates up to 56 people will benefit from the injectable form of the medicine in the first 12 months.

Published

A hand holds a small glass vial upside down while a syringe needle pierces its rubber stopper to draw out medicine.

From 1 December, Pharmac will fund injectable letermovir to prevent cytomegalovirus (CMV) infection in people who have had an allogenic haematopoietic stem cell transplant (allo-HSCT) or who are severely immunosuppressed.

The medicine is already funded as a tablet. Pharmac estimates up to 56 people will benefit from the injectable form in its first 12 months.

“CMV stays in the body for life without causing problems for most people but can cause serious illness in people whose immune systems are not working properly, particularly those who have had an allo-HSCT,” said Michaela Lion, Pharmac’s Manager Pharmaceutical Funding.

Lion described CMV as a common, usually harmless virus that most people are exposed to in childhood. Letermovir works by stopping the virus from becoming active, she added.

The new decision follows Pharmac’s choice on 1 May this year to fund letermovir in tablet form. Clinicians advised Pharmac that relying only on tablets could make accurate dosing difficult for some patients. Tablets may also not suit patients who have trouble swallowing them.

Tablets will stay funded and available alongside the injectable form. They can be used in hospitals and community pharmacies.

Since letermovir was funded earlier this year, pharmacists and clinicians have reported no cases of CMV reactivation or infection in this group of patients, Lion said. She called it tremendous to hear.

Stopping CMV can lower the risk of serious illness and complications, according to Lion. It can also spare people long hospital stays and intensive treatment, and help them recover at home sooner, spending less time away from whānau.

Source: Pharmac (opens in a new tab) · More from Pharmac on Keepwell
Checked against the source on . How this site works
Spotted a mistake? Report an error